Focus: Edgewise is a public-stage biotechnology company focused on small-molecule therapeutics for musculoskeletal diseases, particularly muscular dystrophies. The company operates as a lean, early-stage biotech with a focused pipeline and minimal commercial infrastructure to date.
Profile data last refreshed 55m ago · AI intelligence enriched 2w ago
Best suited for early-stage biotech believers willing to accept binary risk in exchange for potential ground-floor equity upside in rare disease muscular dystrophy.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Edgewise Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Edgewise Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Recent peer-reviewed publications with author affiliations at this company
Motor Function and Growth Outcomes With Early Corticosteroid Initiation in Duchenne Muscular Dystrophy: An Adjusted Cross-Trial Comparison.
IL-18 Binding Protein, a biomarker of strength maintenance after surgery but reduced physical performance in age-related sarcopenia.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo